As social media, texting and internet use have become a part of daily life, researchers have observed the strong presence of cyberbullying and have begun to show concern about its effects. And while many may presume that bullying is mostly a problem in in the gradeschool years, a new study shows that college students are engaging in these behaviors as well.
The study led by Dr. Ellen Selkie, adolescent medicine doctor at Seattle Children’s Hospital and researcher in the Center for Child Health, Behavior, and Development, published in Cyberpsychology, Behavior, and Social Networking, found that more than 1 in 4 females have experienced cyberbullying in college, thus increasing their risk for depression three-fold. Furthermore, the study found that those who acted as the bullies were more likely to report problematic alcohol abuse and also depression. Read full post »
Jack sits with his uncle (right) who donated his kidney to him.
It can be hard enough to remember to take a multivitamin every day; imagine having to take 20 pills at specific times throughout the day, every day, for your whole life. That’s the reality individuals who have undergone an organ transplant must face. In order to stay healthy and to keep their bodies from rejecting their transplanted organ, a myriad of medications must be taken daily, including immunosuppressants. It can be a difficult pill to swallow, especially for teenagers.
According to research studies, adolescents have the worst outcomes after transplant out of any age group. Adolescents also have the highest rate of non-adherence, which means they either decide not to take their medication or just plain forget, which can lead to the rejection of the organ.
“You can imagine taking that many medications every day could get a little old. It’s a major burden to put on a teenager,” said Dr. Jodi Smith, medical director of kidney transplant at Seattle Children’s Hospital, and a researcher with the Center for Clinical and Translational Research (CCTR). “They were not meant to have this much stuff going on in their life. But if you don’t take your meds, you’ll eventfully need another kidney transplant, and once you lose one it’s harder to get another.” Read full post »
After Olivia Bush was diagnosed with single-suture craniosynostosis, her parents did not know how her brain would develop over time. A new study led by Seattle Children’s is addressing these concerns.
Seattle Children’s researchers have published the results of a 10-year, multi-site study tracking the cognitive development of children with single-suture craniosynostosis from infancy to school age. The results could help families and clinicians better predict which children with this condition are at greater risk of having learning deficits so that they might intervene early in the child’s life.
The study, published today by the American Academy of Pediatrics and titled “Intellectual and Academic Functioning of School-Age Children with Single-Suture Craniosynostosis,” reported children with single-suture craniosynostosis, on average, were more likely than children without the disorder to have learning deficits once they started school. However, despite this trend, a little over half of the children with single-suture craniosynostosis showed no discernible learning problems.
Living with the unknown
The research is significant for parents like Cindy and Todd Bush. Twelve years ago, Cindy and Todd learned their 3-month-old daughter, Olivia, had craniosynostosis, a condition in which one or more of the special joints in a baby’s skull (sutures) grow together (fuse) earlier than normal. When these joints come together too early, a baby’s skull cannot grow properly. Craniosynostosis occurs in approximately one in 1700-2500 live births. Corrective surgery to restore the suture is preferentially performed in the first year of life. Read full post »
A study released today, co-authored by environmental medicine expert Dr. Sheela Sathyanarayana of the Seattle Children’s Research Institute Center for Child Health, Behavior and Development, reports male infants whose mothers were exposed to chemicals called phthalates during pregnancy may have a greater risk of future infertility and other reproductive health issues.
The study, published in the journal Human Reproduction, included over 700 infants and demonstrated that even at low levels, environmental exposure to these common chemicals can adversely affect male genital development, which in turn may impact male reproductive health later in life. Read full post »
Dr. Elizabeth Aylward is director of Seattle Children’s Research Institute’s Office of Science-Industry Partnerships.
While there are approximately 10,000 children in the United States living with lupus, a lifelong disease that causes inflammation throughout the body, there are currently no U.S. Food and Drug Administration (FDA) approved medications to treat these kids, forcing physicians to prescribe medications that are approved for adult patients but may not be appropriate for developing bodies.
It’s a problem that impacts all areas of pediatric medicine. In 2013, the FDA in total approved 27 new drugs; just seven of these were approved for pediatric use. Of the 55,000 clinical trials conducted between 2005 and 2010, only 9% were designed for children.
“Funding for pediatric research lags disproportionately behind research funding for adult diseases. Thirty percent of the U.S. population is under the age of 21, and yet only 6% of the entire National Institutes of Health’s budget is devoted to pediatric medicine and care,” said Dr. Jim Hendricks, president of Seattle Children’s Research Institute. “This gap results in limited development of new therapies for children, who now often have no other choice than to use adult-only tested medications.”
Seattle Children’s is hoping to bridge the gap between promising research and potential treatments and cures for pediatric diseases by partnering with drug manufacturers and biotech companies through its new Office of Science-Industry Partnerships. Read full post »
Dr. Stephen Seslar prepares for a complicated surgery using a new, realistic heart model created with 3-D printing.
Kami Sutton, 26, who you met last week, has been waiting for a heart transplant for five years. But surgeons at Seattle Children’s and University of Washington Medical Center (UWMC) are now preparing to perform a difficult surgery that could greatly improve her quality of life and may even eliminate her need for a transplant. It’s possible for the first time ever, thanks to a new, realistic heart model created with 3-D printing. Read full post »
Dr. Sandra “Sunny” Juul recently became the new Division Chief of Neonatology at Seattle Children’s Hospital and the University of Washington, taking the helm from Dr. Christine Gleason, who stepped down to pursue other professional goals. Below, Juul talks about her vision for her own research and for the Division of Neonatology at Seattle Children’s.
Dr. Sandra “Sunny” Juul, the new Division Chief of Neonatology at Seattle Children’s Hospital
Neonatology is a relatively new field of medical practice, having come into its own in the 1960s. At that time, survival for extremely premature babies and many of those with congenital disorders was low. Through experience and research, infants who were previously destined to die now survive, yet their outcomes are frequently burdened by significant neurodevelopmental challenges.
As a neonatologist, I am honored to participate in the care of precious, fragile individuals ranging from extremely preterm infants to term neonates with complex medical or surgical problems. These small patients and their families humble me with their endurance in the face of great adversity.
I believe that our current mandate as neonatologists is to ensure that survivors of these previously fatal conditions can lead fully functional lives without impairment. In order to accomplish these audacious goals, we have committed, as a division, to improve neonatal outcomes by providing outstanding evidence-based neonatal clinical care, moving our field forward by conducting research, and by educating the next generation of neonatal caregivers. Read full post »
Jennifer Bevaart’s son William was diagnosed with Kawasaki disease in September, 2014.
In honor of National Kawasaki Disease Awareness Day, we are sharing the story of William, a 10-year-old boy who lives with the disease, and why Seattle Children’s, an international leader in Kawasaki disease research, is the best place for children like William to receive treatment.
In September, Jennifer Bevaart’s son William developed a fever that lasted for days. He was lethargic, had a rash on his chest and his eyes were bloodshot. Over the next two weeks, Bevaart took William to at least four different specialists, each of whom suggested a different diagnosis: a sinus infection, walking pneumonia, bronchitis, even scarlet fever. Each treatment failed to ease William’s symptoms. He went from an active, tae kwon do enthusiast to a weak boy who was too weak to walk even the short distance to the mailbox without lying down to rest.
“Call it mother’s intuition, but I just knew something was very wrong with my son,” Bevaart said. “I felt like I was watching him die.” Read full post »
Now that the halls have been decked and the most wonderful time of the year is over, Dr. Jim Hendricks, president of Seattle Children’s Research Institute, took down the holiday tinsel from his work station and spent a moment reflecting on the research institute’s greatest accomplishments of 2014.
There were so many exciting developments over the past year that it’s impossible to fit them all in one short list, but here are some outstanding achievements that come to mind.
- Our investigators had an incredibly successful year when it comes to funding, including government, nonprofit and industry sources. Our total funding increased from $76 million in fiscal year 2013 to nearly $92 million in fiscal year 2014, which represents a 21% increase. This success is a testament to the talent of our investigators considering that the competition for federal grants has increased steadily as the available federal funding has decreased. This funding will help us get closer to finding more treatments and cures for pediatric diseases.
- We continued our first T cell cancer immunotherapy clinical trial this year and opened enrollment for two additional trials. This ground-breaking therapy reprograms the body’s infection-fighting T cells to find and destroy cancer cells with minimal side effects. While our first trial, PLAT-01, continues treating patients with relapsed leukemia, a second trial treating leukemia patients with T cell immunotherapy has had great success thus far. Additionally, a new trial opened in November to treat neuroblastoma using immunotherapy.
Read full post »
As we head into the New Year, we’d like to reflect on some of the incredible clinical advancements of 2014 that show how our doctors have gone the extra mile for our patients.
In the Children’s HealthLink Special video above, watch how futuristic medicine has saved the lives of the littlest patients at Seattle Children’s. From 3D-printed heart models to liquid ventilation, doctors and families reveal the amazing benefits of innovative treatments that challenge the status quo. Read full post »